PolyPeptide Group AGPLYGF 56 Pretax Margin % is 4.90% as of Dec. 2025, which is 44% below its 10-year median of 8.76. GuruFocus rates PLYGF with a GF Score™ of 56/100 and a GF Value™ of $26.83 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 953 Drug Manufacturers companies, PolyPeptide Group AG ranks worse than 73.24% on this metric.
The historical rank and industry rank for PolyPeptide Group AG's Pretax Margin % or its related term are showing as below:
PLYGF'
s Pretax Margin % Range Over the Past 10 Years
Min: -17.93 Med: 8.76 Max: 20.92
Current: -5.15
PLYGF's Pretax Margin % is ranked worse than 73.24% of 953
companies
in the Drug Manufacturers industry
Industry Median: 7.29
vs PLYGF: -5.15
PolyPeptide Group AG (OTCPK:PLYGF) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
PolyPeptide Group AG Pretax Margin % Related Terms
PolyPeptide Group AG Pretax Margin % Historical Data
* Premium members only.
The historical data trend for PolyPeptide Group AG's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PLYGF vs ZTS, UTHR, VTRS: Pretax Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PolyPeptide Group AG's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PolyPeptide Group AG Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PolyPeptide Group AG's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where PolyPeptide Group AG's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PolyPeptide Group AG (PLYGF) has a Pretax Margin % of 4.90% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on PolyPeptide Group AG and its competitors. This is 44% below median its historical median of 8.76. According to the industry distribution chart, PolyPeptide Group AG ranks #698 out of 953 companies in the Drug Manufacturers industry, placing it in the top 73.2%.
Is PolyPeptide Group AG's Pretax Margin % too high?
PolyPeptide Group AG's current Pretax Margin % of 4.90% is 44% below median its 10-year median of 8.76. The Drug Manufacturers industry median Pretax Margin % is 7.29. PolyPeptide Group AG's value of 4.90% is 32.8% below this industry median. Based on the distribution chart, PolyPeptide Group AG ranks #698 out of 953 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, PolyPeptide Group AG has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PolyPeptide Group AG's Pretax Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PolyPeptide Group AG ranks #698 out of 953 companies for Pretax Margin %. This places PolyPeptide Group AG in the lower half of its industry. The industry median Pretax Margin % is 7.29. PolyPeptide Group AG's value of 4.90% is 32.8% below this benchmark. While the company's 10-year median is 8.76 vs. the industry median of 7.29, PolyPeptide Group AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.29, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PolyPeptide Group AG's current Pretax Margin % of 4.90% is 32.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on PolyPeptide Group AG and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PolyPeptide Group AG's current Pretax Margin % is 4.90%, which is 44% below median its own 10-year median of 8.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PolyPeptide Group AG stock overvalued right now?
Based on GuruFocus' analysis, PolyPeptide Group AG (PLYGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $26.83, compared to a current price of $43.00 — trading 60.3% above its estimated fair value. The current Pretax Margin % is 4.90%, which is 44% below median its 10-year median of 8.76 and 32.8% below the Drug Manufacturers industry median of 7.29. PolyPeptide Group AG's overall GF Score™ is 56/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For PolyPeptide Group AG (PLYGF), the current Pretax Margin % is 4.90% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PolyPeptide Group AG (PLYGF) Overvalued in 2026?
Based on GuruFocus' analysis, PolyPeptide Group AG stock appears to be overvalued.
The current stock price of $43.00 is trading 60.3% above its estimated GF Value™ of $26.83.
GuruFocus considers PolyPeptide Group AG to be Significantly Overvalued.
Key valuation signals for PLYGF:
Pretax Margin %: 4.90% (44% below median its 10-year median of 8.76)
GF Value™: $26.83 vs. price of $43.00 (60.3% above fair value)
Industry Position: 32.8% below the Drug Manufacturers median (#698 of 953)
No single metric tells the full story. See the PLYGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PolyPeptide Group AG is an independent contract development and manufacturing organization (CDMO) focused on peptides and oligonucleotides employed as an active pharmaceutical ingredients (APIs) and used as intermediates in therapeutic products. The company derives majority of its revenue from Europe and Asia.
56GF Score
Get the complete analysis for PLYGF
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PLYGF has been successfully added to your 
